Magazine article Clinical Psychiatry News

Adjunctive Aripiprazole Reduces Hospitalization

Magazine article Clinical Psychiatry News

Adjunctive Aripiprazole Reduces Hospitalization

Article excerpt

CHICAGO -- Using aripiprazole for augmentation therapy in adults with bipolar disorder already on a mood stabilizer resulted in significantly fewer hospitalizations than augmentation with other atypical antipsychotics in a large retrospective study.

The explanation for this finding in a real-world claims database appears to lie in a greater willingness on the part of psychiatrists to dose aripiprazole (Abilify) within its optimally effective range, Dr. Edward Kim said at the American Psychiatric Association's Institute on Psychiatric Services.

"I'm not arguing that aripiprazole would be more effective at avoiding psychiatric hospitalization than the other drugs if they were compared in a head-to-head randomized fixed-dose, forced-titration trial. I would expect them to perform equally there.

"My point is that in clinical practice, doctors apparently find it easier to prescribe aripiprazole in effective recommended doses than some of the other second-generation antipsychotics. I suspect that's largely because of concern about side effects with the others," Dr. Kim of Bristol-Myers Squibb, Plainsboro, N.J., said in an interview.

He reported on 6,162 adults on a mood stabilizer for bipolar disorder in the LabRx integrated claims database, all of whom were placed on an adjunctive second-generation atypical antipsychotic chosen by their psychiatrists. In the analysis, patients on aripiprazole were matched to similar ones on other atypical antipsychotics based upon age, gender, locale, prior psychiatric hospitalizations and other medical comorbidities. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.